

Simon De Denus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/193460/publications.pdf>

Version: 2024-02-01

42
papers

994
citations

567281

15
h-index

454955

30
g-index

42
all docs

42
docs citations

42
times ranked

2687
citing authors

#	ARTICLE	IF	CITATIONS
1	Rate vs Rhythm Control in Patients With Atrial Fibrillation. Archives of Internal Medicine, 2005, 165, 258.	3.8	214
2	Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. Nature Genetics, 2014, 46, 629-634.	21.4	113
3	Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Pharmacotherapy, 2020, 40, 40-54.	2.6	83
4	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. American Journal of Human Genetics, 2016, 99, 40-55.	6.2	82
5	Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction. American Heart Journal, 2006, 152, 705-712.	2.7	60
6	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. American Journal of Human Genetics, 2016, 99, 8-21.	6.2	60
7	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. American Journal of Human Genetics, 2016, 99, 22-39.	6.2	50
8	Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw. Canadian Journal of Cardiology, 2017, 33, 283-286.	1.7	34
9	Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan. Annals of Pharmacotherapy, 2008, 42, 925-932.	1.9	33
10	<i>CYP2D6</i> polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis. British Journal of Clinical Pharmacology, 2020, 86, 1015-1033.	2.4	30
11	Risk Factors for Chronic Renal Insufficiency Following Cardiac Transplantation. Annals of Transplantation, 2015, 20, 576-587.	0.9	25
12	Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review. Pharmacogenomics, 2015, 16, 755-767.	1.3	23
13	Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. Journal of Heart and Lung Transplantation, 2011, 30, 326-331.	0.6	19
14	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clinical Cardiology, 2018, 41, 576-585.	1.8	19
15	Subclinical Inflammation in Heart Failure: A Neutrophil Perspective. Canadian Journal of Cardiology, 2018, 34, 717-725.	1.7	16
16	Changes in Cardiopulmonary Reserve and Peripheral Arterial Function Concomitantly with Subclinical Inflammation and Oxidative Stress in Patients with Heart Failure with Preserved Ejection Fraction. International Journal of Vascular Medicine, 2014, 2014, 1-8.	1.0	14
17	Temporal Increases in Subclinical Levels of Inflammation Are Associated With Adverse Clinical Outcomes in Patients With Left Ventricular Dysfunction. Journal of Cardiac Failure, 2006, 12, 353-359.	1.7	11
18	Pharmacogenomics of heart failure: a systematic review. Pharmacogenomics, 2016, 17, 1817-1858.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists. <i>Pharmacogenomics</i> , 2020, 21, 235-245.	1.3	10
20	Key Articles and Guidelines in the Management of Hypertension. <i>Pharmacotherapy</i> , 2004, 24, 1385-1399.	2.6	9
21	A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial. <i>American Heart Journal</i> , 2018, 204, 190-195.	2.7	7
22	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003183.	3.6	7
23	Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof-of-concept study. <i>Clinical and Translational Science</i> , 2022, 15, 1063-1073.	3.1	7
24	An association study of <i>ABCG2</i> rs2231142 on the concentrations of allopurinol and its metabolites. <i>Clinical and Translational Science</i> , 0, , .	3.1	7
25	Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring – further insights from SOLVD. <i>Canadian Journal of Cardiology</i> , 2008, 24, 45-48.	1.7	6
26	Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 837-847.	1.9	6
27	Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies. <i>JMIR Research Protocols</i> , 2017, 6, e102.	1.0	6
28	Will personalized drugs for cardiovascular disease become an option? – Defining “Evidence-based personalized medicine”™ for its implementation and future use. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2549-2552.	1.8	5
29	Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. <i>Pharmacotherapy</i> , 2021, 41, 379-393.	2.6	5
30	Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 81-90.	1.9	4
31	Isocyanate derivatization coupled with phospholipid removal microelution-solid phase extraction for the simultaneous quantification of (S)-metoprolol and (S)- \pm -hydroxymetoprolol in human plasma with LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 204, 114263.	2.8	4
32	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021, 12, 812018.	3.5	4
33	Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. <i>Clinical and Translational Science</i> , 2021, 14, 194-203.	3.1	3
34	Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. <i>ESC Heart Failure</i> , 2022, 9, 2997-3008.	3.1	3
35	Cardiopulmonary, biomarkers, and vascular responses to acute hypoxia following cardiac transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13352.	1.6	2
36	Pharmacogenomics and Heart Failure in Congenital Heart Disease. <i>Canadian Journal of Cardiology</i> , 2013, 29, 779-785.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Personalizing the management of heart failure in congenital heart disease: challenges and opportunities. <i>Pharmacogenomics</i> , 2014, 15, 123-127.	1.3	1
38	Heart Failure, Iron Deficiency, and Supplementation: Where Do We Stand?. <i>Canadian Journal of Cardiology</i> , 2016, 32, 148-150.	1.7	1
39	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
40	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
41	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
42	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0